Is There a Role for Proliferation Signal/mTOR Inhibitors in the Prevention and Treatment of De Novo Malignancies After Heart Transplantation? Lessons Learned From Renal Transplantation and Oncology

Journal of Heart and Lung Transplantation

Volumn 26, Issue 6, 2007, Pages 557-564

  Valantine, Hannah ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AP 23573; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TACROLIMUS; TEMSIROLIMUS;

ACUTE GRAFT REJECTION; ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CANCER RISK; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; PHOTOSENSITIVITY; PRIORITY JOURNAL; REVIEW; SKIN CANCER; SOLID TUMOR; SURVIVAL TIME; TREATMENT OUTCOME;

AZATHIOPRINE; CYCLOSPORINE; ENZYME INHIBITORS; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROTEIN KINASES; RISK; RISK FACTORS; TACROLIMUS;

EID: 34249308123     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2007.03.010     Document Type: Review

References (53)

1. Hosenpud J.D., Bennett L.E., Keck B.M., Boucek M.M., and Novick R.J. The registry of the International Society for Heart and Lung Transplantation: eighteenth official report-2001. J Heart Lung Transplant 20 (2001) 805-815
2. Kirklin J.K., Naftel D.C., Bourge R.C., et al. Evolving trends in risk profiles and causes of death after heart transplantation: a ten-year multi-institutional study. J Thorac Cardiovasc Surg 125 (2003) 881-890
3. Opelz G., and Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4 (2003) 222-230
4. Gjersvik P., Hansen S., Moller B., et al. Are heart transplant recipients more likely to develop skin cancer than kidney transplant recipients?. Transplant Int 13 suppl (2000) S380-S381
5. Ulrich C., Schmook T., Sachse M.M., Sterry W., and Stockfleth E. Comparative epidemiology and pathogenic factors for non-melanoma skin cancer in organ transplant patients. Dermatol Surg 30 (2004) 622-627
6. Chapman J., and Webster A. Cancer. In: Excell L., and McDonald S. (Eds). ANZDATA registry report (2004), Australia and New Zealand Dialysis and Transplant Registry, Adelaide 100-103
7. ANZDATA. Australia and New Zealand Dialysis and Transplant Registry, 2006. Available at: http://www.anzdata.org.au/. Accessed January 2006.
8. Penn I. Cancers in renal transplant recipients. Adv Renal Replace Ther 7 (2000) 147-156
9. Rubio E., Moreno J.M., Turrion V.S., et al. De novo malignancies and liver transplantation. Transplant Proc 35 (2003) 1896-1897
10. Vallejo G.H., Romero C.J., and de Vicente J.C. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol 56 (2005) 87-99
11. Baccarani U., Adani G.L., Montanaro D., et al. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases. Transplant Proc 38 (2006) 1135-1137
12. Morath C., Mueller M., Goldschmidt H., Schwenger V., Opelz G., and Zeier M. Malignancy in renal transplantation. J Am Soc Nephrol 15 (2004) 1582-1588
13. O'Donovan P., Perrett C.M., Zhang X., et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309 (2005) 1871-1874
14. Hojo M., Morimoto T., Maluccio M., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397 (1999) 530-534
15. Jensen P., Moller B., and Hansen S. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens [letter]. J Am Acad Dermatol 42 (2000) 307
16. Dantal J., Hourmant M., Cantarovich D., et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporine regimens. Lancet 351 (1998) 623-628
17. Neumayer H.-H. Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments. Transplantation 79 suppl (2005) S72-S75
18. Rapamune summary of product characteristics (2001), Wyeth Europa, Ltd, Maidenhead, UK
19. Oberbauer R., Segoloni G., Campistol J.M., et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int 18 (2005) 22-28
20. Schweiger M., Wasler A., Prenner G., et al. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients. Transplant Immunol 16 (2006) 46-51
21. Lehmkuhl H., Ross H., Eisen H., and Valantine H. Everolimus (Certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure. Transplant Proc 37 (2005) 4145-4149
22. Vitko S., Tedesco H., Eris J., et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 4 (2004) 626-635
23. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91 (2004) 1420-1424
24. Xu Q., Simpson S.E., Scialla T.J., Bagg A., and Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102 (2003) 972-980
25. Law M., Forrester E., Chytil A., et al. Rapamycin disrupts cyclin/cyclin-dependent kinase/p21/proliferating cell nuclear antigen complexes and cyclin D1 reverses rapamycin action by stabilizing these complexes. Cancer Res 66 (2006) 1070-1080
26. Mita M.M., Mita A., and Rowinsky E.K. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 4 (2003) 126-137
27. Kunnimalaiyaan M., Ndiaye M., and Chen H. Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery 140 (2006) 1009-1015
28. Bais C., Van Geelen A., Eroles P., et al. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell 3 (2003) 131-143
29. Beuvink I., Boulay A., Fumagalli S., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120 (2005) 747-759
30. Majewski M., Korecka M., Kossev P., et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 97 (2000) 4285-4290
31. Majewski M., Korecka M., Joergensen J., et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 75 (2003) 1710-1717
32. Guba M., von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Med 8 (2002) 128-135
33. Luan F.L., Hojo M., Maluccio M., Yamaji K., and Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 73 (2002) 1565-1572
34. Kauffman H.M., Cherikh W.S., Cheng Y., Hanto D.W., and Kahan B.D. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80 (2005) 883-889
35. Mathew T., Kreis H., and Friend P. Two-year incidence of malignancy in sirolimus-treated transplant recipients: results from five multicenter studies. Clin Transplant 18 (2004) 446-449
36. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk of cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581-589
37. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 1317-1323
38. Campistol J.M., Gutierrez-Dalmau A., and Torregrosa J.V. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 77 (2004) 760-762
39. Vignot S., Faivre S., Aguirre D., and Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16 (2005) 525-537
40. Witzig T.E., and Kaufmann S.H. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 7 (2006) 285-294
41. Tabernero J., Rojo F., Burris H., et al. A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients with advanced solid tumors. J Clin Oncol 23 (2005)
42. Jac J., Sharef S., Khan M., and Amato R.J. Rapamycin for androgen-independent prostate cancer (AIPC) (2006) American Society of Clinical Oncology, 2006 Prostate Cancer Symposium, (abstract 257)
43. Das A., Badruddoja M., Tryciecky D., Yu J., and Black K. Phase I study of gefitinib and rapamycin in patients with recurrent or progressive glioblastoma (GBM). J Clin Oncol 23 (2005)
44. Albanell J., Rojo F., Averbuch S., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20 (2002) 110-124
45. Andres V., Castro C., and Campistol J.M. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients. Nephrol Dial Transplant 21 suppl 3 (2006) iii14-iii17
46. Kasiske B.L., Snyder J.J., Gilbertson D.T., and Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 4 (2004) 905-913
47. Smith J.M., Rudser K., Gillen D., et al. Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System. Transplantation 81 (2006) 175-180
48. Farge D., and The Collaborative Transplantation Research Group of Ile de France. Kaposi's sarcoma in organ transplant recipients. Eur J Med 2 (1993) 339-343
49. Fortina A.B., Caforio A.L., Piaserico S., et al. Skin cancer in heart transplant recipients: frequency and risk factor analysis. J Heart Lung Transplant 19 (2000) 249-255
50. Kremers W.K., Devarbhavi H.C., Wiesner R.H., et al. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 6 (2006) 1017-1024
51. Aseni P., Vertemati M., De Carlis L., et al. De novo cancers and post-transplant lymphoproliferative disorder in adult liver transplantation. Pathol Int 56 (2006) 712-715
52. Oo Y.H., Gunson B.K., Lancashire R.J., et al. Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. Transplantation 80 (2005) 759-764
53. Herrero J.I., Espana A., Quiroga J., et al. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transplant 11 (2005) 1100-1106